These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30268412)

  • 21. Surveillance and correlation of antimicrobial usage and resistance of Pseudomonas aeruginosa: a hospital population-based study.
    Xu J; Duan X; Wu H; Zhou Q
    PLoS One; 2013; 8(11):e78604. PubMed ID: 24250801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
    Eagye KJ; Nicolau DP
    Infect Control Hosp Epidemiol; 2010 May; 31(5):485-90. PubMed ID: 20334550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carbapenem stewardship: positive impact on hospital ecology.
    Lima AL; Oliveira PR; Paula AP; Dal-Paz K; Almeida JN; Félix Cda S; Rossi F
    Braz J Infect Dis; 2011; 15(1):1-5. PubMed ID: 21412581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Carbapenem Selection on Drug Acquisition Costs and Carbapenem Resistance.
    Smoke SM; Abdul W; Grigoriu A; Vasant D
    J Pharm Pract; 2019 Feb; 32(1):7-8. PubMed ID: 29587577
    [No Abstract]   [Full Text] [Related]  

  • 25. Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates.
    Pires dos Santos R; Jacoby T; Pires Machado D; Lisboa T; Gastal SL; Nagel FM; Kuplich NM; Konkewicz L; Gorniak Lovatto C; Pires MR; Goldani LZ
    Infect Control Hosp Epidemiol; 2011 Jun; 32(6):584-90. PubMed ID: 21558771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance emergence among P. aenrginosa in a rat thigh-abscess model. Comparison of imipenem and meropenem treatment.
    Karadenizli A; Kolayli F; Okay E; Ergen K; Oz S; Savli H; Leblebicioglu H; Vahaboglu H
    New Microbiol; 2003 Jul; 26(3):275-80. PubMed ID: 12901424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units.
    Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Bakšytė G; Macas A; Sakalauskas R
    Medicina (Kaunas); 2011; 47(12):652-6. PubMed ID: 22370463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa.
    Harashima S; Kondo H; Nabeshima A; Shimoda M; Yamaji K; Horiuchi T; Shimono N; Ikematsu H
    J Infect Chemother; 2008 Jun; 14(3):219-22. PubMed ID: 18574658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa.
    Margaret BS; Drusano GL; Standiford HC
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():161-7. PubMed ID: 2509413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of Pseudomonas aeruginosa with discrepant carbapenem susceptibility profile.
    Pragasam AK; Raghanivedha M; Anandan S; Veeraraghavan B
    Ann Clin Microbiol Antimicrob; 2016 Feb; 15():12. PubMed ID: 26911874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia.
    Apisarnthanarak A; Kiratisin P; Apisarnthanarak P; Mundy LM
    Infect Control Hosp Epidemiol; 2011 Apr; 32(4):410-1. PubMed ID: 21460501
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial susceptibility testing of carbapenems: multicenter validity testing and accuracy levels of five antimicrobial test methods for detecting resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolates.
    Steward CD; Mohammed JM; Swenson JM; Stocker SA; Williams PP; Gaynes RP; McGowan JE; Tenover FC
    J Clin Microbiol; 2003 Jan; 41(1):351-8. PubMed ID: 12517872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
    Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
    Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa.
    Pakyz AL; Oinonen M; Polk RE
    Antimicrob Agents Chemother; 2009 May; 53(5):1983-6. PubMed ID: 19273670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.